With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged for more pull incentives.
https://european-biotechnology.com/wp-content/uploads/2024/04/AMR_Conference_sponsoren_neu_kl.jpg6751200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-09-01 12:33:002020-09-01 12:33:00Stakeholders push for further pull incentives
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-08-27 14:26:392020-08-27 14:26:39Immunovia appoints Patrik Dahlen as new CEO
British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
https://european-biotechnology.com/wp-content/uploads/2024/04/SARS-CoV-2_Credit_NIAID-RML.jpg383450Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-08-25 08:18:002020-08-25 08:18:00Moderna set to deliver COVID-19 jab to the EU
Roche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19.
https://european-biotechnology.com/wp-content/uploads/2024/04/2020_08_20_abigail-herron-7226.jpg336496h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-08-20 06:49:552024-05-02 13:35:52The role of investors in addressing AMR
Stakeholders push for further pull incentives
Latest NewsWith around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged for more pull incentives.
Bioversys bags €17.7m financing
Latest NewsSwiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
Sotio licences Unum Therapeutics’ CAR-T cell portfolio
Latest NewsPPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.
Polyphor partners with Fosun Pharma
Latest NewsPolyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China.
Immunovia appoints Patrik Dahlen as new CEO
AppointmentsSwedish diagnostic company Immunovia AB announces Patrik Dahlen as new CEO starting November 2020.
Engitix Ltd. lands US$500m deal with Takeda in fibrosis
Latest NewsBritish fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
Moderna set to deliver COVID-19 jab to the EU
Latest NewsUS experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists map ulcerative colitis
Latest NewsScientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
COVID-19: Roche and Regeneron join forces
Latest NewsRoche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19.
The role of investors in addressing AMR
OpinionAbigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it.